v3.26.1
Segment Information (Tables)
 6 Months Ended
Jun. 30, 2026
Segment Reporting [Abstract]  
Schedule of Significant Expense Categories Provided to CODM

The following table is representative of the significant expense categories regularly provided to the CODM when managing the Company’s single reportable segment (in thousands):

 

 

Three Months Ended
June 30,

 

 

2026

 

 

2025

 

Revenues(1)

 

$

287

 

 

$

316

 

Less:

 

 

 

 

 

 

Cost of revenues

 

 

105

 

 

 

170

 

R&D costs(2)

 

 

952

 

 

 

739

 

G&A costs(3)

 

 

1,904

 

 

 

1,387

 

Personnel costs(4)

 

 

3,065

 

 

 

2,961

 

Other segment items(5)

 

 

334

 

 

 

87

 

Net loss

 

$

(6,073

)

 

$

(5,028

)

 

 

Six Months Ended
June 30,

 

 

2026

 

 

2025

 

Revenues(1)

 

$

685

 

 

$

697

 

Less:

 

 

 

 

 

 

Cost of revenues

 

 

239

 

 

 

276

 

R&D costs(2)

 

 

1,524

 

 

 

1,225

 

G&A costs(3)

 

 

3,589

 

 

 

2,788

 

Personnel costs(4)

 

 

5,503

 

 

 

5,983

 

Other segment items(5)

 

 

639

 

 

 

464

 

Net loss

 

$

(10,809

)

 

$

(10,039

)

(1) Includes Contract Manufacturing and Clinical Trial revenue

(2) Includes Clinical Development, Research & Discovery, CMC

(3) Includes Executive, Finance, Legal, Business Operations

(4) Includes compensation, benefits and equity-based compensation

(5) Includes depreciation and amortization, (interest income) and other specific charges